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This study aims to detect and clarify signals of serious skin reactions associated with 
benzodiazepine anticonvulsant therapy in the FDA Adverse Event Reporting System 
(FAERS). Methods: Cases reported to FAERS between 1997 and 2012 were retrieved. 
The MedDRA Preferred Terms were used to define serious skin reactions. Individual 
anticonvulsant benzodiazepines were identified by generic names. Empirical Bayes 
Geometric Mean (EBGM) with 95% confidence interval (EB05-EB95) were calculated 
as disproportionality measures. Drug-event combinations with EB05≥ 2 were con-
sidered signals that warrant further review. Results: 4,411 reports of serious skin 
reactions were submitted for all anticonvulsant agents. 6.3% were for benzodiaz-
epines (279), corresponding to: clobazam (33), clonazepam (54), clorazepate (41), 
diazepam (82), and lorazepam (69). Signals were detected for clorazepate (EBGM 9.6 
EB05-EB95 7.4-12.4) and clobazam (EBGM 8.7 EB05-EB95 6.4-11.5). Disproportional 
reporting was found for other benzodiazepines, albeit didn’t reach signal threshold: 
diazepam (EBGM 2.3 EB05-EB95 1.9-2.8), lorazepam (EBGM 2.2 EB05-EB95 1.8-2.7), and 
clonazepam (EBGM 1.5 EB05-EB95 1.2-1.9). Eighty one (29%) reported serious skin 
events were fatal, corresponding to: clobazam (7), clonazepam (12), clorazepate (16), 
diazepam (30), and lorazepam (16). Most of reported events listed patient exposure 
to ≥ 2 concomitant drugs at event occurrence time. ConClusions: Anticonvulsant 
therapy with benzodiazepines, particularly clobazam and clorazepate, might be 
associated with serious skin reactions. In concordance with FDA’s recommenda-
tion, patients should seek immediate help when dermal signs and symptoms are 
appeared and alternative anticonvulsant agent should be considered by prescribers. 
Signal evaluation activities are required to further characterize this risk.
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objeCtives: This retrospective study examined the temporal relationship of diag-
nosis, treatment, health care utilization, and clinical outcomes in patients with 
Tuberous Sclerosis (TSC)-related renal angiomyolipoma in the US. Methods: 
Patients with ≥ 1 diagnosis of TSC (ICD-9-CM 759.5) and angiomyolipoma (ICD-9-CM 
223.0 and other codes) were extracted from the MarketScan® Commercial Database 
1/1/2000 - 3/31/2013. Patients were followed from the first diagnosis of TSC or angio-
myolipoma (index date) until inpatient death or end of study follow-up. During the 
follow-up, proportion of patients with each event and days from index date to event 
(among those with the event) were reported. An innovative graph was explored to 
describe the natural history of events in this population. Results: The final sample 
consisted of 605 patients (mean age 26.8): 225 patients age< 18 (mean age 9.8, 55% 
female, median follow-up 3.4 years) and 380 patients age≥ 18 (mean age 36.9, 73% 
female, median follow-up 2.2 years). In patients < 18, 87% had TSC diagnosis before 
angiomyolipoma (angiomyolipoma was diagnosed 25.7 months after TSC on aver-
age), 2.8% had complete nephrectomy (8.5 months after index date); emergency 
room (ER) visit, 61% (16.6 months); inpatient admission, 48% (17.0 months); chronic 
kidney disease (CKD), 12% (32.3 months); embolization, 11% (36.2 months); end 
stage renal disease (ESRD), 1.3% (40.9 months); and 1.4% partial nephrectomy (42.0 
months). In patients ≥ 18, 56% had TSC diagnosis before angiomyolipoma (angiomy-
olipoma was diagnosed 16.9 months after TSC), ER visit, 56% (9.9 months); inpatient 
admission, 50% (11.3 months); partial nephrectomy, 7.9% (11.9 months); complete 
nephrectomy, 11.4% (13.9 months); CKD, 23% (15.1 months); embolization, 19% (17.1 
months); and ESRD, 5.3% (20.1 months). ConClusions: This study suggested that 
time from a TSC diagnosis to an angiomyolipoma diagnosis was long and sometimes 
was preceded with ER visits, hospitalizations and surgeries. The innovative graphing 
of natural history can help raise disease awareness in TSC.
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objeCtives: To assess real-world effectiveness, based on registry data, of natali-
zumab in multiple sclerosis (MS) patients with highly active relapsing-remitting MS 
(RRMS). Methods: Phase IV, observational, retrospective, multi-center database 
analysis on data from the period January 2009 – January 2013. Statistical analy-
ses were performed using Kaplan-Meier and Cox PH regression. Inclusion criteria 
comprised adults aged ≥ 18 with high disease activity with rapidly evolving severe 
RRMS or a relapse despite treatment with beta-interferon or glatiramer acetate. The 
main outcome measure was change from annualized baseline relapse rate (ARR), 
with secondary endpoints comprising sustained disability progression and improve-
ment at 12/24 months, and change in the mean Expanded Disability Status Scale 
(EDSS). Change from baseline ARR comprised ARR absolute values, relative reduc-
tion (percentage), and percentage of patients remaining relapse-free. Analyses were 
presented using frequency tables, crosstabs, graphics and, for EDSS survival analysis 
was conducted. Subgroup analyses were conducted for age, gender and prior treat-
ment received. Results: A total of 216 individuals (72% of whom females) were 
included in the study. Mean age at onset of MS was 27 years, 29 years at diagnosis, 
38 years at start of natalizumab therapy. A significant decrease in mean ARR was 
seen after 12 months compared to baseline (N= 216; Δ = 0.76; p-value< 0.001), and 
between the first and second years of treatment (N= 208; Δ = 0.06; p-value= 0.030). 
There was no significant variation across subgroups. Mean EDSS changed from 3.26 
at baseline to 3.02 at 12 months and 3.16 at 24 months. No new safety concerns 
were noted. ConClusions: Natalizumab treatment in Hungary was associated 
with two-year effectiveness as shown by reduced ARR and stabilized EDSS over the 
observation period. These results are important for decision-makers striving to 
burden of disease(n= 17). Registry-data was used in 3 studies to validate/assess 
generalizability. All modeling studies combined registry with non-registry-data (e.g. 
RCT). ConClusions: Registries provide a rich source of information on real-world 
patients which are being incorporated into health economic analyses. Although 
Nordic registry-data is being utilized in HE studies, many analyses important to HE 
are not represented. These preliminary findings suggest that HE should continue to 
broaden the use and application of registry-data in the field of rheumatic disease. 
Given the gap in data required for an economic-evaluation (e.g. modeling), research-
ers must continue to be aware of potential issues associated with the synthesis of 
RCT and registry-data.
Pms84
PrelimiNary results of multiDisciPliNary systematic folloW-uP of 
fragility fractures iN ortHoPaeDic cliNic
Fernandes J.1, Delisle J.1, Perreault S.2, Beaumont P.1, Gagnon S.1, Giroux M.3, Jodoin A.1, 
Laflamme Y.1, Leduc S.1, MacThiong J.M.1, Malo M.1, Maurais G.1, Nguyen H.3, Parent S.1, 
Ranger P.1, Raynauld J.P.R.4, Rouleau D.1, Troyanov Y.1
1Hôpital du Sacré Coeur de Montréal, Montreal, QC, Canada, 2Université de Montréal, Montréal, 
QC, Canada, 3Hôpital Jean Talon, Montreal, QC, Canada, 4Institut de Rhumatologie de Montréal, 
Montreal, QC, Canada
objeCtives: Despite the major health care impact worldwide of fragility fracture, 
there are few systems in place to identify and capture subjects after a fragility frac-
ture to ensure appropriate assessment and treatment to reduce future fracture risk 
and adverse outcomes. We implemented a multidisciplinary systematic follow-up 
of fragility fractures to close the care gap. Methods: We recruited 543 subjects 
over 40 years of age who sustained a fragility fracture at the orthopaedic clinic of 
Hôpital du Sacré-Cœur de Montréal or Hôpital Jean-Talon hospital from July 2010 
to 2013. Demographic and clinical data were assessed over 18-months of follow-up. 
We analysed data of patients who have completed at least 18 months of follow-up 
(women n= 99; men n= 16). We described demographic data, BMD, perceived compli-
ance to treatment, and subsequent fracture rates. We assessed the effect on bone 
markers and vitamin D levels using T-test. Results: Mean age was at 61 years. 
The common fracture site was the wrist (40%) followed by the ankle and proximal 
humerus (13%), vertebrae (10%) and hip (7%). Close to 41.7% of women and 20% of 
men had already sustained a previous fragility fracture. At 18 months, 10.1% of 
women and 6.3% of men had already sustained a new fracture. High CTX-1 levels 
(> 0.3 ng/mL) dropped from 46.7% to 21.4% for women and 61.5% to 23.1% for men 
after 18 months of treatment (p< 0.01). Low Vitamin D levels (< 80 nmol/L) increased 
from 63% to 87.5% for women and 16.7% to 83.3% for men (p< 0.00001). Women and 
men perceived they were still persistent and adherent to treatment at 18 months in 
90% and 88% of the time, respectively. ConClusions: Better diagnostic tools and 
systematic management of the fragility fractures and compliance monitoring can 
lower the refracture rates in the long term in this at-risk population.
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objeCtives: In 2005, a quality measure was added to the Healthcare Effectiveness 
Data and Information Set (HEDIS) that quantifies the proportion of rheumatoid 
arthritis (RA) patients who receive disease modifying anti-rheumatic drug (DMARD) 
therapy in a given year. This study describes annual trends in the HEDIS RA manage-
ment quality measure among commercially- and Medicare supplemental-insured 
U.S. RA patients from 2005 to 2012. Methods: This was a retrospective observa-
tional study based on U.S. administrative claims data. Patients selected for study 
during a given measurement year were aged ≥ 18 years, had continuous insurance 
enrollment throughout the year, and had two outpatient claims, on different days, 
with a diagnosis of RA (ICD-9-CM codes 714.0, 714.1, 714.2, 714.81). Receipt of a 
biologic or non-biologic DMARD therapy was assessed annually from 2005 to 2012. 
Bivariate statistics were used to test for differences across the years. Results: 
Annual sample sizes averaged ~95,000 RA patients. From 2005 to 2012, the RA qual-
ity measure was stable at approximately 83% of RA patients receiving DMARD 
treatment. Biologic DMARD utilization increased from 32% in 2005 to 39% in 2012 
(p< 0.001), whereas use of non-biologic DMARDs decreased slightly from 74% to 72% 
(p< 0.001). Among the subset of patients aged ≥ 65 years with Medicare Supplemental 
insurance, the RA quality measure was slightly lower at approximately 78% receiving 
DMARD therapy. Fewer RA patients with Medicare Supplemental insurance received 
biologic DMARDs, however, utilization increased from 23% in 2005 to 29% in 2012 
(p< 0.001). In the same time period, non-biologic DMARD use decreased from 73% to 
69% (p< 0.001). ConClusions: Since the 2005 introduction of the HEDIS RA man-
agement quality measure, increases in the use of biologic DMARD therapy were 
offset by decreases in the use of non-biologic DMARD therapy. Findings suggest 
potential room for improvement in the quality of care for RA patients.
Neurological DisorDers – clinical outcomes studies
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objeCtives: In late 2013, the FDA announced to the public that clobazam is linked 
to serious skin events, including Stevens-Johnson syndrome (SJS), toxic epidermal 
necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP), and con-
sequently approved changes to clobazam label and medication guide. However, no 
comparative pharmacovigilance analysis was conducted for other anticonvulsant 
benzodiazepines, including clonazepam, clorazepate, diazepam, and lorazepam. 
